{"id":75557,"date":"2026-08-20T11:53:48","date_gmt":"2026-08-20T03:53:48","guid":{"rendered":"https:\/\/flcube.com\/?p=75557"},"modified":"2026-08-20T11:53:50","modified_gmt":"2026-08-20T03:53:50","slug":"leo-pharma-to-acquire-global-rights-to-dersimelagon-from-tanabe-late-stage-oral-therapy-for-rare-protoporphyrias-nears-fda-decision","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75557","title":{"rendered":"LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe \u2013 Late\u2011Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision"},"content":{"rendered":"\n

LEO Pharma A\/S<\/strong> announced that it has entered into an agreement with Tanabe Pharmaceutical<\/strong> to acquire the global rights to dersimelagon<\/strong>, an oral small\u2011molecule melanocortin 1 receptor (MC1R) agonist<\/strong> in late\u2011stage development for erythropoietic protoporphyria (EPP)<\/strong> and X\u2011linked protoporphyria (XLP)<\/strong>. The deal enriches the Danish dermatology specialist’s late\u2011stage R&D pipeline in rare dermatological diseases.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>LEO Pharma A\/S (Denmark)<\/td><\/tr>
Counterparty<\/strong><\/td>Tanabe Pharmaceutical<\/td><\/tr>
Asset<\/strong><\/td>Dersimelagon \u2013 oral small\u2011molecule MC1R agonist<\/td><\/tr>
Scope<\/strong><\/td>Global rights<\/td><\/tr>
Stage<\/strong><\/td>Post\u2011Phase III; NDA under FDA review<\/td><\/tr>
Announcement Date<\/strong><\/td>18 Aug 2026<\/td><\/tr>
Strategic Rationale<\/strong><\/td>Deepens LEO Pharma’s late\u2011stage pipeline in rare dermatological diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n